Bluebird bio to be acquired by Carlyle and SK Capital
According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital to scale Bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Bluebird Bio has had 900+ patent applications, and 200 granted patents published across 88 patent families between 2009 and 2024.
Bluebird Bio has filed more than 900 patent application since 2005, the majority filed since 2014.
Analysing their portfolio by number of applications by priority shows two peak filing periods - Patent filings has seen two peaks 2014 and 2016.
The innovation pipeline looks reasonably healthy. Application filings within the past ten years account for a majority of their filings. Since 2020 there are fewer applications - this may indicate patents filed within the past fives years have yet to be published.
Sources: